Compare · ABCM vs CRL
ABCM vs CRL
Side-by-side comparison of Abcam plc (ABCM) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABCM focuses on Biotechnology: Biological Products (No Diagnostic Substances), while CRL focuses on Biotechnology: Commercial Physical & Biological Resarch.
- CRL is the larger of the two at $13.22B, about 2.9x ABCM ($4.59B).
- CRL has hit the wire 9 times in the past 4 weeks while ABCM has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 3 for ABCM).
- Company
- Abcam plc
- Charles River Laboratories International Inc.
- Price
- $23.98+0.00%
- $276.61+3.48%
- Market cap
- $4.59B
- $13.22B
- 1M return
- -
- +18.38%
- 1Y return
- -
- +85.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2000
- News (4w)
- 0
- 9
- Recent ratings
- 3
- 25
Abcam plc
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest ABCM
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form 15-12G filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form POSASR filed by Abcam plc
- SEC Form SC 13D/A filed by Abcam plc (Amendment)
- SEC Form 25-NSE filed by Abcam plc
- Danaher Completes Acquisition of Abcam
Latest CRL
- SVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)
- EVP & Chief People Officer Creamer Victoria L sold $1,083,030 worth of shares (4,179 units at $259.16) and exercised 4,179 shares at a strike of $179.66 (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M sold $1,327,098 worth of shares (5,046 units at $263.00) as part of a pre-agreed trading plan, decreasing direct ownership by 51% to 4,807 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.
- Charles River upgraded by Analyst with a new price target
- SEC Form 10-Q filed by Charles River Laboratories International Inc.
- Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Charles River Laboratories Announces Second-Quarter 2026 Results
- Charles River downgraded by CLSA with a new price target
- Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call